| Tender Details | ||||||||
                    
  | 
            ||||||||
| Deadline * | ||||||||
                        
  | 
                ||||||||
| Client Address | ||||||||
                        
  | 
                ||||||||
| More Information | ||||||||
| Know More | ||||||||
Similar Tenders
- Ref No: 4641405
 - Location: Germany
 
Medicines With The Active Ingredient Aclidinium Bromide Atc R03Bb05
- Deadline: 28 Feb 2026
 
- Ref No: 5393652
 - Location: Germany
 
Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Fampridine N3
- Deadline: 10 Nov 2025
 
- Ref No: 5837360
 - Location: Germany
 
Conclusion Of A Non Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For Blood Sugar Test Strips
- Deadline: 10 May 2026
 
- Ref No: 5227070
 - Location: Germany
 
Medicines With The Active Ingredient Dupilumab Atc D11Ah05
- Deadline: 31 Mar 2026
 
- Ref No: 5229599
 - Location: Germany
 
Medicines With The Active Ingredient Fampridine Atc N07Xx07
- Deadline: 31 Mar 2026
 
- Ref No: 5965414
 - Location: Germany
 
Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Acarbose Not In Standard Size
- Deadline: 10 May 2026
 
- Ref No: 8267412
 - Location: Germany
 
Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Brinzolamide Brimonidine Atr
- Deadline: 10 May 2026
 
- Ref No: 8294730
 - Location: Germany
 
Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Para 8 Sgb V For The Active Ingredient Omalizumab
- Deadline: 10 Aug 2026
 
- Ref No: 8309306
 - Location: Germany
 
Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Pomalidomide
- Deadline: 10 May 2026
 
- Ref No: 8312368
 - Location: Germany
 
Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Bosutinib
- Deadline: 10 May 2026
 
- Ref No: 5716614
 - Location: Germany
 
Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Para 8 Sgb V For The Active Ingredient Rituximab
- Deadline: 11 May 2026
 
- Ref No: 5718497
 - Location: Germany
 
Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Tocilizumab
- Deadline: 11 May 2026
 
- Ref No: 5728730
 - Location: Germany
 
Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Bevacizumab
- Deadline: 10 May 2026
 
- Ref No: 5730369
 - Location: Germany
 
Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Ranibizumab
- Deadline: 10 May 2026